Overview

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine

Status:
Not yet recruiting

Trial end date:
2027-07-01

Target enrollment:

Participant gender:

Summary

The goal of this double-blind randomized controlled trial is to determine if combination therapy of statin and low-dose colchicine - compared with statin alone - favorably modulates progression and composition of subclinical coronary atherosclerosis in individuals with high polygenic risk for coronary artery disease.

Phase:

Phase 4

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Colchicine
Rosuvastatin Calcium